Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haoyuan Chemexpress Co Buyback Yield % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Haoyuan Chemexpress Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Haoyuan Chemexpress Co Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shanghai Haoyuan Chemexpress Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Shanghai Haoyuan Chemexpress Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Haoyuan Chemexpress Co (SHSE:688131) has a Buyback Yield % of 0.00 as of Aug. 20, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Shanghai Haoyuan Chemexpress Co and its competitors. According to the industry distribution chart, Shanghai Haoyuan Chemexpress Co ranks #999999 out of 257 companies in the Drug Manufacturers industry.
Is Shanghai Haoyuan Chemexpress Co's Buyback Yield % too high?
Shanghai Haoyuan Chemexpress Co's current Buyback Yield % is 0.00. Based on the distribution chart, Shanghai Haoyuan Chemexpress Co ranks #999999 out of 257 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shanghai Haoyuan Chemexpress Co has a GF Score™ of 86/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Haoyuan Chemexpress Co's Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shanghai Haoyuan Chemexpress Co ranks #999999 out of 257 companies for Buyback Yield %. This places Shanghai Haoyuan Chemexpress Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Shanghai Haoyuan Chemexpress Co and its competitors. Shanghai Haoyuan Chemexpress Co's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Haoyuan Chemexpress Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co (SHSE:688131) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥66.97, compared to a current price of ¥100.09 — trading 49.5% above its estimated fair value. The current Buyback Yield % is 0.00. Shanghai Haoyuan Chemexpress Co's overall GF Score™ is 86/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Shanghai Haoyuan Chemexpress Co (SHSE:688131), the current Buyback Yield % is 0.00 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Haoyuan Chemexpress Co (SHSE:688131) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Haoyuan Chemexpress Co stock appears to be overvalued.
The current stock price of ¥100.09 is trading 49.5% above its estimated GF Value™ of ¥66.97.
GuruFocus considers Shanghai Haoyuan Chemexpress Co to be Significantly Overvalued.
Key valuation signals for SHSE:688131:
Buyback Yield %: 0.00
GF Value™: ¥66.97 vs. price of ¥100.09 (49.5% above fair value)
No single metric tells the full story. See the SHSE:688131 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Haoyuan Chemexpress Co Ltd focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. The company's comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. It is a one-stop service platform to support client's projects from early drug discovery, process development to commercialization. The company is committed to delivering high-quality products and CMC services to clients across the entire life cycle of drug development.
86GF Score
Get the complete analysis for SHSE:688131
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688131 has been successfully added to your 
